UC Davis study: TB vaccine shrinks liver cancer tumors in mice

AI-based blood test outperforms ultrasound in early liver cancer detection

Helio Genomics, an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, has released results from its latest clinical trial demonstrating the superior performance of their HelioLiver Dx test compared to ultrasound.

June 14, 2024

Vol.50 No.24

Clinical Roundup

Innovative PET scanner could change the way lung cancer is evaluated and treatment is assessed

Scientists at UC Davis Comprehensive Cancer and the UC Davis Department of Radiology have discovered a novel way to image the unique blood supply of the lungs. Their findings, published in the Journal of Nuclear Medicine, suggest the new method could help determine if lung cancer treatment is working.

June 14, 2024

Vol.50 No.24

Clinical Roundup

Liver surgery to remove cancer can now be a safe outpatient procedure

Robotic liver surgery can be a safe outpatient procedure, according to a study published in the Journal of the American College of Surgeons. In fact, 8% of the patients sampled in the analysis were discharged to go home on the same day.

June 14, 2024

Vol.50 No.24

In Brief

David Tom Cooke named associate director of Office of Inclusion, Diversity, Equity and Accessibility at UC Davis

David Tom Cooke was named associate director of the Office of Inclusion, Diversity, Equity and Accessibility (IDEAL) at University of California Davis Comprehensive Cancer Center.

May 17, 2024

Vol.50 No.20

In Brief

Mauricio Garcia named Jerome S. Levy, MD, Chair in Gastroenterology and Hepatology at UAMS

The University of Arkansas for Medical Sciences College of Medicine invested Mauricio S. Garcia in the Jerome S. Levy, MD, Chair in Gastroenterology and Hepatology during a May 1 ceremony.

May 10, 2024

Vol.50 No.19

Clinical Roundup

Imfinzi regimen reduces the risk of disease progression or death in liver cancer eligible for embolization

Positive results from the EMERALD-1 phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with transarterial chemoembolization, or TACE, and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival compared to TACE alone in patients with hepatocellular carcinoma eligible for embolization.

March 29, 2024

Vol.50 No.13

UC Davis study: TB vaccine shrinks liver cancer tumors in mice

YOU MAY BE INTERESTED IN

AI-based blood test outperforms ultrasound in early liver cancer detection

Innovative PET scanner could change the way lung cancer is evaluated and treatment is assessed

Liver surgery to remove cancer can now be a safe outpatient procedure

David Tom Cooke named associate director of Office of Inclusion, Diversity, Equity and Accessibility at UC Davis

Mauricio Garcia named Jerome S. Levy, MD, Chair in Gastroenterology and Hepatology at UAMS

Imfinzi regimen reduces the risk of disease progression or death in liver cancer eligible for embolization

Renew today!

Subscriber content

Login